Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients

Clin Infect Dis. 2020 Nov 19;71(16):2227-2229. doi: 10.1093/cid/ciaa394.

Abstract

Hydroxychloroquine (HCQ) appears to be a promising treatment for COVID-19. However, all ongoing clinical trials with HCQ use different dosing regimens, resulting in various concentrations. Pharmacokinetic studies are therefore needed to define the optimal dosing regimen.

Keywords: COVID-19; SARS-Cov2; hydroxychloroquine; intensive care; pharmacokinetic.

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • COVID-19 / drug therapy*
  • Dose-Response Relationship, Drug
  • Female
  • France
  • Humans
  • Hydroxychloroquine / administration & dosage*
  • Hydroxychloroquine / pharmacokinetics*
  • Intensive Care Units
  • Male
  • Middle Aged
  • Prospective Studies

Substances

  • Hydroxychloroquine

Supplementary concepts

  • COVID-19 drug treatment